Customer No. 28880

## Confirmation No.

PC25562A

Date | May 17, 2004

FW

PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 1. are required to respond to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Application Number 10/811,200 **TRANSMITTAL** Filing Date MARCH 26, 2004 **FORM** First Named Inventor Wayne L. Cody et al Art Unit (to be used for all correspondence after initial filing) **Examiner Name** 

**Attorney Docket Number** 

Total Number of Pages in This Submission	Attorney Booker Humber	PC25562A
	ENCLOSURES (Check all that appl	(y)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Remarks  AUTHORIZATION TO CHARGE THE INECESSARY OR CREDIT ANY OVERI 21-0718 IS HEREBY GIVEN.	After Allowance Communication to a Technology Center (TC)  Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below): Retrun Postcard Copies of all cited references except U.S. Patents  FEE AND ANY ADDITIONAL FEES AS PAYMENT TO DEPOSIT ACCOUNT
SIGNA	TURE OF APPLICANT, ATTORNEY,	OR AGENT .
Firm or Individual Andrew J. Leon Signature May 17, 2004	Kun	
C	ERTIFICATE OF TRANSMISSION/MA	AILING

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ih ereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as

first class mail in an envelope addressed to:Commissioner for Patents, P.O.Box 1450, Alexandra, VA 22313-1450 on this date May 17, 2004

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Typed or printed

Signature

Hetzler

Diane L

PC25562A



APPLICANT: Wayne L. Cody et al EXAMINER:

SERIAL NO. : 10/811,200 ART UNIT

FILED: March 26, 2004 PAPER NO

FOR : PIPERIDINE DERIVATIVE RENIN INHIBITORS

## **INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))**

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d); or before the mailing of the first Office Action on the merits.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Except for United States Patents and United States Patent Application Publications.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art."

10/811,200 PC25562A

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dated: May 17, 2004

Respectfully submitted,

Andrew J.Leon

Registration No. 46,869

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Telephone: (734) 622-4047 Facsimile: (734) 622-1553

Customer No. 28880

Sheet 1

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

Under the Paperwork Reduction Act 07/995, respectors are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/811,200				
Filing Date	March 26, 2004				
First Named Inventor	Wayne L. Cody et al				
Art Unit					
Examiner Name					
Attorney Docket Number	DC25562A				

				DOCUMENTS	
Examiner Cit Initials* No	Cite No.1	Document Number  Number-Kind Code <sup>2 (Atro wn)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages,C olumns, Lines, Where Relevant Passages or Relevan Figures Appear
		<sup>US-</sup> 6,051,712	04-18-2000	Hoffman-La Roche Inc	
		<sup>US-</sup> 6,150,526	11-21-2000	Hoffman-La Roche Inc	
		US-			
		US-	·		
		US-			
-		US-			
	_	US-	-		
		US-	·		
.,.		US-			
		US-			
		US-			
<del></del>		US-			
		US-			
		US-	<del>-  </del>		
		US-			
		US-			

		FORE	<b>IGN PATENT DOCL</b>	JMENTS	•	
Examiner Cite Initials* No.1	Foreign PatentD ocument	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO03/093267 A1	11-13-2003	ACTE-LION		
		WO00/64887 A1	11-02-2000	F. HOFFMAN		
		WO02/076440 A2	10-03-2002	ELAN PHARM		
		WO00/64873 A1	11-02-2000	F. HOFFMAN		
		WO01/74796 A1	10-11-2001	Dupont Pharm		
		WO01/22964 A1	04-05-2001	Georgetown Un		Г

Examiner		Date	
Signature	•	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Customer No. 28880

Sheet 2

Under the Paperwork Reduction Substitute for form 1449/PTO

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

Report 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	ilpiete il Kilowii	
Application Number	10/811,200	
Filing Date	March 26, 2004	
First Named Inventor	Wayne L. Cody et al	
Art Unit		
Examiner Name		
Attornoy Docket Number	DC25562A	

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (fino wn)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages,C olumns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-	-		3
		US-			
_		US-			
		US-			
******		US-			
		US-			

Cite No.1	Foreign PatentD ocument	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code <sup>3 -</sup> Number <sup>4 -</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T®
	WO99/65867 A1	12-23-1999	DuPont Pharm		
					_
					<u> </u>
		No. 1 Foreign PatentD ocument  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Cite No. 1 Publication Date MM-DD-YYYY  Country Code 2 Number 4 Kind Code 5 (if known)	No.1 Date Applicant of Cited Document MM-DD-YYYY  Country Code3 Number 1 Kind Code5 (if known)	Cite No. 1 Publication Date Applicant of Cited Document Where Relevant Passages Or Relevant Figures Appear  Country Code 3 Number 4 Kind Code 5 (if known)  Publication Date Applicant of Cited Document Where Relevant Passages Or Relevant Figures Appear

Examiner	Date	-
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

Substitu	te for form 1449/PTO				Complete if Known
			Application Number	10/811,200	
INF	ORMATION	DIS	CLOSURE	Filing Date	March 26, 2004
STA	STATEMENT BY APPLICANT		First Named Inventor	Wayne L. Cody et al	
	///	-4		Art Unit	
	(Use as many she	ets as n	ecessary)	Examiner Name	
Sheet	3	of	3	Attorney Docket Number	PC25562A

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MARKI, H.P. ET AL., "Piperidine renin inhibitors: from leads to drug candidates", Il Farmaco (2001), VOL. 56, PAGES 21-27	
		OEFNER, C.; BINGGELI ET AL., "Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?", Chemistry & Biology 1999, Vol. 6, pages 127-131	
		GULLER, R.; BINGGELI et al., "Piperidine-Renin inhibitors Compounds With Improved Pysicochemical Properties", Bioorg. Med. Chem. Lett. 1999, Vol. 9, pages 1403-1408	
		VIEIRA, E.; BINGGELI et al., "Substituted Piperidines-Highly Potent Renin Inhibitors Due To Induced Fit Adaptation of The Active Site", Bioorg. Med. Chem. Lett. 1999, Vol. 9, pages 1397-1402	
		RAHUEL, J.; RASETTI et al., "Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin", Chemistry & Biology 2000, Vol. 7, pages 493-504	
		BURSAVICH, M. G.;et al., "The Mechanism of Reations Catalysed By The Serine Beta-Lactamases", Ogr. Lett. 2001, Vol. 3, No. 15 pages 2317-2320	

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.